Old Westbury, New York 11568


Fatigue affects more than half of people living with Parkinson's disease. Despite its prevalence, treatment options remain limited. To improve patient outcome, a group treatment protocol was developed for PD fatigue management primarily using cognitive behavioral therapy. The program focuses on assisting individuals with PD who experience fatigue to establish proper sleep hygiene habits and a physical exercise routine to meet the end goal of reducing fatigue. The aim of the group is to change negative thoughts and behavior regarding changing sleep hygiene habits and exercise behavior into positive ones. This is a feasibility project that aims to explore the feasibility of this protocol as well as to produce a treatment protocol that is able to be replicated by other occupational therapists and health professionals who serve the PD population.

Study summary:

PD is the second most common neurodegenerative disorder in the United States. Although PD is typically classified as a movement disorder, the non-motor symptoms (NMS) also have a negative impact on quality of life. Among the NMS, fatigue is one of the most reported and bothersome symptoms, even at the early stage of the disease. Currently there are not any clear pharmacological or rehabilitative recommendations for managing PD related fatigue. The purpose of this study is to evaluate the feasibility and effectiveness of a developed treatment protocol specifically adapted to the Parkinson's population to address fatigue symptoms based on the best available evidence. This is a one-group, pre-post, feasibility study. It is hypothesized that an establishment of a proper sleep hygiene routine and a moderate- to intensive-exercise routine three times a week will decrease Parkinson's disease (PD) related fatigue and improve health-related quality of life. The treatment protocol focuses on assisting individuals with PD experiencing fatigue to improve sleep hygiene habits and establish physical exercise routine using cognitive behavioral therapy in a group format. Through this study, the designed program will be evaluated to determine if it will decrease self-perceived fatigue level and to improve health-related quality of life among community dwelling people with PD.


Inclusion Criteria: 1. All subjects must be diagnosed with PD, without the diagnosis of Lewy Body dementia. Atypical parkinsonism such as Progressive Supranuclear Palsy, Corticobasal Degeneration, and Multiple System Atrophy are excluded. 2. All participants of the program are community dwelling. 3. Subjects must age between 21 and 80. There is no gender limitation. 4. All subjects report feeling sense of fatigue. 5. Because the intervention involves encouraging individuals to participate in highly-intense physical exercise or multimodal moderately-intense physical exercise, cardiovascular clearance from each participant's physician (either primary care, internist, or cardiologist) is required. See attachment for cardiovascular clearance letter. 6. Because cognitive behavioral therapy will be used in the interventions, and safety judgment is required when choosing an appropriate physical exercise during interventions, participants must present with adequate cognitive capacity. The Montreal Cognitive Assessment (MoCA) will be used to determine if the individual meets the cognitive criteria. MoCA score must be 24 or above, or 21 to 23 with an accompany of a caregiver to participate (MoCA total score is 30). In PD, individuals with mild neurocognitive disorder (NCD), with MoCA score 21 to 23, are able to perform everyday activities independently, although with greater effort, compensatory strategies, or accommodation Exclusion Criteria: 1. MoCA score 22 or below 2. Unable to obtain physician clearance for exercise participation 3. Diagnosis of Lewy Body dementia. Atypical parkinsonism

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

Treatment Protocol for PD Fatigue Management With CBT

Official Title:

A Treatment Protocol for Management of Fatigue in Parkinson's Disease Using Cognitive Behavioral Therapy

Overall Status:


Study Phase:




Minimum Age:

21 Years

Maximum Age:

80 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

New York Institute of Technology

Oversight Authority:

There was an error processing this request

Reasons Why Stopped:

Study Type:


Study Design:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Ling Wan-Albert, MS
Principal Investigator
New York Institute of Technology
Primary Contact:Ling Wan-Albert, MS

Study Dates

Start Date:October 19, 2018
Completion Date:October 18, 2019
Completion Type:Anticipated
Primary Completion Date:October 18, 2019
Primary Completion Type:Anticipated
Verification Date:November 2018
Last Changed Date:November 19, 2018
First Received Date:October 31, 2018

Study Outcomes

Outcome Type:Secondary Outcome
Measure:Parkinson's Disease Quality of Life Questionnaire (PDQ-39)
Time Frame:0-week, 6-week, 12-week. This is to measure the change between three points. 0-week indicates pre-tr
Safety Issues:False
Description:Measurement of self-report health-related quality of life. There are 39 items, grouped in 8 subscales: Mobility (10 items), Activities of daily living (6 items), Emotional well-being (6 items), Stigma (4 items), Social support (3 items), Cognitions (4 ite
Outcome Type:Secondary Outcome
Measure:Parkinson's Sleep Scale (PDSS-2)
Time Frame:0-week, 6-week, 12-week. This is to measure the change between three points. 0-week indicates pre-tr
Safety Issues:False
Description:Measurement of self-report quality of sleep. There are 15 items about various sleep and nocturnal disturbance; rated on a 5-point scale ranging from "never"=0, occasional"=1, "sometimes"=2, "often"=3 to "very often"=4. Total scores range from 0 to 60, wi
Outcome Type:Secondary Outcome
Measure:Sleep Hygiene Index (SHI)
Time Frame:0-week, 6-week, 12-week. This is to measure the change between three points. 0-week indicates pre-tr
Safety Issues:False
Description:Measurement of self-report sleep hygiene behavior. There are 13-item, on a five-point scale ranging from "never"=0, "rarely"=1, "sometimes"=2, "frequent"=3, to "always"=4. Total scores range from 0 to 52, with a higher score representing poorer sleep hyg
Outcome Type:Primary Outcome
Measure:Modified Fatigue Impact Scale (MFIS)
Time Frame:0-week, 6-week, 12-week. This is to measure the change between three points. 0-week indicates pre-tr
Safety Issues:False
Description:Measurement of self-report fatigue level. There are 21 items on a 5-point scale- subjects rate from "Never"=0, "Rarely"=1, "Sometimes"=2, "Often"=3, to "Always"=4. MFIS can be aggregated into three subscales: physical, cognitive, and psychosocial. Total

Study Interventions

Intervention Type:Behavioral
Name:CBT group
Description:Each interested individual will complete eligibility screening, consent form, and pre-intervention assessment. Demographic information such as gender, age, and number of years since diagnosis of PD will be collected. This investigator will implement the treatment program by meeting with the participants in groups, once a week, for six weeks. Group meetings will encourage interaction and support among group participants. Program content includes encouraging physical exercise with higher intensity
Arm Name:CBT group

Study Arms

Study Arm Type:Experimental
Arm Name:CBT group
Description:Subjects will participate in group treatment sessions (once a week for six weeks).

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:New York Institute of Technology

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

If you would like to be contacted by the clinical trial representative please fill out the form below.